SLDB Q1 2022 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$644M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-42.3% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$25M-1318.0% margin

Net Income

-$25M-1315.7% margin

EPS (Diluted)

$-3.37

QoQ Revenue Growth

-39.0%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$208M

Total Liabilities

$22M

Stockholders' Equity

$186M

Cash & Equivalents

$130M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-42.3%
Gross Profit	$2M	$3M	-42.3%
Operating Income	-$25M	-$17M	-50.3%
Net Income	-$25M	-$17M	-49.9%